<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5090711 Figure_1-A-B</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 1-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>(A-B) Western-Blotting (WB) of p53-negative lung cancer H1299 cells stably expressing (A) or transiently expressing (B) the indicated constructs. Post-translationally modified &#916;133p53 and &#916;160p53 isoforms are indicated with *.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_1-C</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) The same WB membrane containing lysates from R273Hp53-expressing A431cells was incubated with rabbit polyclonal CM-1 antibody and mouse monoclonal 1801 antibody against the N-terminus of p53. Detection using anti-rabbit IRDye 680LT (red) and anti-mouse IRDye 800CW (green) secondary antibodies confirmed that the &#916;160p53 band corresponds to a C-terminal isoform of p53.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_1-D</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>(D) WB of H1299 cells transiently expressing the indicated constructs.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_1-E</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) WB of cell lines expressing wild-type (HCT116, U2OS, A549) or mutant (SW480 [R273H/P309S], MDAMB231 [R280K], A431 [R273H], HT29 [R273H] and SKBR3 [R175H]) p53.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_1-F</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 1-F</infon>
    <infon key="sourcedata_figure_dir">Figure_1-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) Cell lines harbouring endogenous wild-type (A549) or R273H mutant (A431) p53 were treated or not with control siRNA (ctl) or siRNA targeting both p53 transcripts (ex6 and ex7), full-length mRNA only (ex2/3) or &#916;133p53 mRNA only (in4) before lysis and WB.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_1-G</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 1-G</infon>
    <infon key="sourcedata_figure_dir">Figure_1-G</infon>
    <passage>
      <offset>0</offset>
      <text>(G) WB of H1299 cells stably expressing R273Hp53 and treated with DMSO, proteasome inhibitor MG132 or mRNA translation inhibitor cycloheximide (CHX). Shown are representative data of three independent experiments. The numbers in parenthesis indicate the amounts of protein for the indicated bands according to WB quantifications and normalization against &#945;-tubulin or GAPDH and relative to the value indicated in bold and set to 1.0. In WBs for endogenous p53 cell lines the &#916;160 lane is used as a marker lane showing &#916;160p53 as transiently expressed in p53-null H1299 cells.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_2-A</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Cell lines endogenously expressing mutant R273Hp53 (A431 and HT29) were treated with control siRNA (ctl) or siRNA targeting exon 7 of p53, submitted to endoplasmic reticulum (ER) stress by exposure to thapsigargin (Th) and then analysed for apoptosis by incubation with propidium-iodide (PI) and FACS analysis. Data was normalized against si ctl condition, which was set to 100.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_2-B</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B and C) A549 (B) lung cancer cell lines stably expressing the indicated constructs were counted with Trypan blue for several days following stress stimuli (over-confluency (O-C) for A549). Data was normalized against 1st day values. &#916;160p53 shows similar pro-proliferative capacities as mutant R273Hp53. On the other hand R273Hp53 lost pro-proliferative functions when deficient for &#916;160p53 expression (M160AR273Hp53). Also shown is the WB of A549 cells used in (B) and stably expressing the indicated constructs.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_2-C</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 2-C</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C</infon>
    <passage>
      <offset>0</offset>
      <text>(B and C) H1299 (C) lung cancer cell lines stably expressing the indicated constructs were counted with Trypan blue for several days following stress stimuli (thapsigargin (Th) for H1299). Data was normalized against 1st day values. &#916;160p53 shows similar pro-proliferative capacities as mutant R273Hp53. On the other hand R273Hp53 lost pro-proliferative functions when deficient for &#916;160p53 expression (M160AR273Hp53).</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_2-D-E</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 2-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_2-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>(D to G) H1299 cells transfected with the indicated constructs were submitted to ER stress (E and G) or cultured under regular conditions (D). Data was normalized against empty vector (E) or p53 (D) condition, which were set to 100. Cells were then analysed for apoptosis as in (A). Shown are representative data or averages + s.d. of three independent experiments (*P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.005 and ^P &gt; 0.05 compared to control ("Th + si ctl" or "-" ) or as indicated).</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_2-F-G</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 2-F-G</infon>
    <infon key="sourcedata_figure_dir">Figure_2-F-G</infon>
    <passage>
      <offset>0</offset>
      <text>(D to G) H1299 cells transfected with the indicated constructs were submitted to ER stress (E and G), DNA-damage by 36h 3 &#956;M etoposide (Eto) treatment (F). Data was normalized against empty vector (E) or p53 (D) condition, which were set to 100. Cells were then analysed for apoptosis as in (A). Shown are representative data or averages + s.d. of three independent experiments (*P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.005 and ^P &gt; 0.05 compared to control ("Th + si ctl" or "-" ) or as indicated).</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_3-A</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) Adhesion assay shows that MCF10A cells stably expressing &#916;133p53, &#916;160p53, R273H&#916;160p53 or missense mutant R273Hp53 adhere more strongly than control cells. Excluding &#916;160p53 expression from the mutant background (M160A/R273Hp53) rescued control-cell phenotype. Scale bar represents 200 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_3-B</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) WB of MCF10A cells used in (A) and stably expressing the indicated constructs. Shown are representative data of three independent experiments and quantifications.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_3-C</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C and D) MCF10A human breast epithelial cells stably expressing the indicated constructs were cultured in matrigel. Control- and &#916;133p53-expressing cells formed regular three-dimensional (3D) mammary acinar structures with hollow lumina but &#916;160p53-, R273H&#916;160p53 and to a smaller extent mutant R273Hp53-expressing cells formed acini with filled lumen and long invasive structures (n &gt; 30 acini per experiment per condition).</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_3-D</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>(C and D) MCF10A human breast epithelial cells stably expressing the indicated constructs were cultured in matrigel. Control- and &#916;133p53-expressing cells formed regular three-dimensional (3D) mammary acinar structures with hollow lumina but &#916;160p53-, R273H&#916;160p53 and to a smaller extent mutant R273Hp53-expressing cells formed acini with filled lumen and long invasive structures (n &gt; 30 acini per experiment per condition).</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_3-E</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>(E) H1299 cells stably expressing empty vector (control) or the indicated constructs were assessed by confocal microscopy for invasion further than 30 &#956;m through a Matrigel-fibronectin matrix towards EGF-supplemented growth media. The 30 &#956;m plane is indicated and scale bars represent 100 &#956;m. Quantifications are shown in the right panel.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_4-A</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>(A) WB of H1299 cells stably expressing &#916;133p53 and treated with control morpholino oligos (Ctl-1 or Ctl-2) or antisense morpholino oligo targeting &#916;160p53's translation initiation (MO)</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_4-B</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>(B) A431 and HT29 cells expressing endogenous mutant R273Hp53 were treated with control morpholinos (Ctl-2 or Ctl-1) or antisense morpholino oligo targeting &#916;160p53's translation initiation site (MO) before lysis and WB. wtp53-expressing A549 cells were used as reference for endogenous wtp53 expression levels. &#916;160 lane was used as a marker lane showing &#916;160p53 as transiently expressed in p53-null H1299 cells.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_4-C</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>(C) Shown are the average &#916;160p53 protein levels expressed in R273Hp53 versus other mutant p53cell lines that were treated with control morpholino (Ctl-1) or morpholino targeting 160p53's translation initiation site (MO). MO efficiently targets 160p53 in endogenous R273Hp53 cell lines. See also figure EV3 for the raw data.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_4-D-E</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 4-D-E</infon>
    <infon key="sourcedata_figure_dir">Figure_4-D-E</infon>
    <passage>
      <offset>0</offset>
      <text>(D-E) A431 (D) and HT29 (E) cells endogenously expressing mutant R273Hp53 were treated with control siRNA (si Ctl) or control MO (MO Ctl-2 or MO Ctl-1) or siRNA targeting exon 7 of p53 (si) or MO targeting &#916;160p53's translation initiation site (MO), as indicated, submitted to endoplasmic reticulum stress by exposure to thapsigargin (Th) and then analysed for apoptosis by incubation with propidium-iodide (PI) and FACS analysis. wtp53-expressing A549 cells were similarly control-treated and used as comparison. Data was normalized against A549 cell condition, which was set to 100.</text>
    </passage>
  </document>
  <document>
    <id>5090711 Figure_4-F</id>
    <infon key="sourcedata_document">2307</infon>
    <infon key="doi">10.15252/embr.201541956</infon>
    <infon key="pmc_id">5090711</infon>
    <infon key="figure">Figure 4-F</infon>
    <infon key="sourcedata_figure_dir">Figure_4-F</infon>
    <passage>
      <offset>0</offset>
      <text>(F) A431 and HT29 cells endogenously expressing mutant R273Hp53 were treated with control morpholino Ctl-1 or morpholino targeting &#916;160p53's translation initiation site (MO) and then assessed by confocal microscopy for invasion further than 30 &#956;m through a Matrigel-fibronectin matrix towards EGF-supplemented growth media. The 30 &#956;m plane is indicated and scale bars represent 100 &#956;m. Quantifications are shown in the right panel.</text>
    </passage>
  </document>
</collection>
